We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Sanofi Sa | LSE:0A2V | London | Ordinary Share | SANOFI ADR REP 1 1/2 ORD (CDI) |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 1,629 | - |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Health & Allied Services,nec | 43.07B | 5.4B | 4.2694 | 21.46 | 115.88B |
TIDM0A2V
RNS Number : 4567I
Citigroup Global Markets Limited
02 December 2022
FORM 38.5(a) (EPT/RI)
IRISH TAKEOVER PANEL
DEALING DISCLOSURE UNDER RULE 38.5(a) OF THE IRISH
TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2022
BY A CONNECTED EXEMPT PRINCIPAL TRADER WITH
RECOGNISED INTERMEDIARY STATUS AND DEALING IN
A CLIENT-SERVING CAPACITY
1. KEY INFORMATION (a) Name of exempt principal trader: Citigroup Global Markets Limited (b) Name of offeror/offeree in relation to whose relevant securities this Sanofi form relates: Use a separate form for each offeror/offeree --------------------------------- (c) Name of the party to the offer with which exempt principal trader is Amgen Inc connected: (Note 1) --------------------------------- (d) Date dealing undertaken: 01 December 2022 --------------------------------- (e) In addition to the company in 1(b) above, is the exempt principal trader Horizon Therapeutics plc and also making Amgen Inc disclosures in respect of any other party to the offer? If it is a cash offer or possible cash offer, state "N/A" --------------------------------- 2. DEALINGS BY THE EXEMPT PRINCIPAL TRADER (Note 2)
Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.
The currency of all prices and other monetary amounts should be stated.
Ap35
(a) Purchases and sales Class Purchases/ Total Highest Lowest of sales number price price relevant of per per security securities unit paid/ unit paid/ (Note received received 3) (EUR) (EUR) ordinary shares Purchase 669,352 91.6400 86.2250 ------------ ------------ ------------ ------------ ordinary shares Sale 461,073 91.6400 86.2250 ------------ ------------ ------------ ------------ (b) Cash-settled derivative transactions Class Product Nature of Number Price of description dealing of per relevant e.g. CFD e.g. opening/closing reference unit security a long/short securities (Note position, (Note 5) increasing/reducing 4) a long/short position ordinary Increasing shares TRS Short Position 2 87.4400 -------------- ----------------------- ------------ -------- ordinary Increasing shares TRS Short Position 61 87.1374 -------------- ----------------------- ------------ -------- ordinary Increasing shares TRS Short Position 1 87.1000 -------------- ----------------------- ------------ -------- (c) Stock-settled derivative transactions (including options) (i) Writing, selling, purchasing or varying Class of Product Writing, Number Exercise Type Expiry Option relevant description purchasing, of price per e.g. date money security e.g. call option selling, securities unit American, paid/ varying etc. to which European received option etc. per unit relates (Note 4) (ii) Exercise Class of Product Exercising/ Number of Exercise price relevant description exercised securities per unit security e.g. call option against (Note 5) (d) Other dealings (including transactions in respect of new securities) Class of relevant security Nature of Details Price per unit dealing (if applicable) e.g. subscription, (Note 5) conversion, exercise
Ap36
3. OTHER INFORMATION (a) Indemnity and other dealing arrangements Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state "none" (b) Agreements, arrangements or understandings relating to options or derivatives Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated. Date of disclosure: 02 December 2022 Contact name: Craig Watson ----------------- Telephone number: 028 90 409605 -----------------
Public disclosures under Rule 38 of the Rules must be made to a Regulatory Information Service.
Ap37
NOTES ON FORM 38.5(a)
1. See the definition of "connected principal trader" in Rule 2.2 of Part A of the Rules.
2. See the definition of "dealing" in Rule 2.1 of Part A of the Rules. 3. See the definition of "relevant securities" in Rule 2.1 of Part A of the Rules. 4. See Rule 2.5(d) of Part A of the Rules.
5. If the economic exposure to changes in the price of securities is limited, for example, by virtue of a stop loss arrangement relating to a spread bet, full details must be given.
6. If details included in a disclosure under Rule 38 are incorrect, they should be corrected as soon as practicable in a subsequent disclosure. Such disclosure should state clearly that it corrects details disclosed previously, identify the disclosure or disclosures being corrected, and provide sufficient detail for the reader to understand the nature of the corrections. In the case of any doubt, the Panel should be consulted.
For full details of disclosure requirements, see Rules 8 and 38 of the Rules. If in doubt, consult the Panel.
References in these notes to "the Rules" are to the Irish Takeover Panel Act, 1997, Takeover Rules, 2022.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
ISEEAFAAEFFAFFA
(END) Dow Jones Newswires
December 02, 2022 06:15 ET (11:15 GMT)
1 Year Sanofi Chart |
1 Month Sanofi Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions